

COVAX AMC

DONORS MEETING

Marie-Ange Saraka-Yao

Managing Director, Resource Mobilisation, Private Sector

Partnerships and Innovative Finance

8 September 2020



Agenda

- 1. Overview of the Gavi COVAX AMC**
- 2. Feedback on the fundraising approach**
- 3. Feedback on the Term Sheet and Grant Agreements**

The AMC aims to achieve equitable access to COVID-19 vaccines

660622

Objective



Accelerating the availability of effective vaccines.



Reserving doses for AMC-eligible economies.



Making vaccines **affordable**.

Impact



Protect health care workers and the most **vulnerable** populations.




Help prevent the transmission of COVID-19 around the world.



Help restart the world's economy by mitigating the impact of the pandemic.

To achieve this target we are raising \$2 billion by end-December 2020 and are launching a second round of funding for at least \$5 billion by end-2021.

COVAX aims to build a large diversified Vx portfolio to secure access to vaccine doses in 2021 660622



US\$ 2 billion are needed by Dec-2020 for APAs and to reserve doses for 2021

660622

Advance Purchase Agreements (APA)



Cash required for advance payment on certain vaccine contracts payable before end-2020

Firm order commitments




Assured resources required to backstop firm order commitments entered before end-2020 and due on delivery

▶ The initial \$2 billion will need to be complemented by further resources in 2021 once reserved doses will be available for purchase.

170 COVAX economies will mutually benefit from large and shared Vx portfolio and diluted risk

660622




The AMC will be funded progressively reflecting the instrument's cash flow requirements

660622

COVAX AMC 

At least \$5 billion to pay for additional procurement costs and operationalisation of COVID programmes in AMC economies



Up front \$2 billion for APAs and firm order commitments¹

(1) Firm order commitments could take the form of financial guarantees

COVAX AMC needs US\$ 2 billion in grants and guarantees for the launch

660622

Fundraising phase

Launch
Jun 2020 – Dec 2020

US\$ 2 billion

Ramp-up
Jan 2021 – Dec 2021

At least US\$ 5 billion

Note: the above figures assume no AMC country co-financing and do not include vaccine delivery and ancillary costs

660622

THANK YOU



Reach every child
www.gavi.org

The overall COVAX cost is estimated at \$17.3 B of which \$6.3 B are required for AMC procurement

660622

Indicative figures as of 01-Sep-20

